Definium Therapeutics
DFTX
104 hedge funds and large institutions have $18M invested in Definium Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 9 closing their positions.
388% more call options, than puts
Call options by funds: $6.76M | Put options by funds: $1.39M
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
48% more capital invested
Capital invested by funds: $12.1M → $18M (+$5.82M)
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
12% more funds holding
Funds holding: 93 → 104 (+11)
2.48% more ownership
Funds ownership: 9.76% → 12.24% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.81M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$442K |
| 3 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$367K |
| 4 |
Jane Street
New York
|
+$280K |
| 5 |
Goldman Sachs
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$390K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$182K |
| 3 |
BB
Busey Bank
Urbana,
Illinois
|
-$151K |
| 4 |
VF
Virtu Financial
New York
|
-$89K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$72.7K |
DFTX Hedge Fund Activity: Q4 2023 in Review
104 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2023, worth a combined $18M — up 48% from $12.1M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DFTX positions and 9 closed out — a net gain of 12 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.81M. The largest seller was Millennium Management, cutting an estimated $390K.
- 104 institutional investors held Definium Therapeutics (DFTX) as of Q4 2023, up from 93 in Q3 2023.
- Funds reported $18M of Definium Therapeutics stock for Q4 2023, up 48% quarter-over-quarter.
- 21 funds opened new Definium Therapeutics positions in Q4 2023 and 9 closed out, a net change of +12 holders.
- The largest Definium Therapeutics buyer in Q4 2023 was Ikarian Capital, an estimated $1.81M added.
- The largest Definium Therapeutics seller in Q4 2023 was Millennium Management, an estimated $390K sold.
Based on aggregated 13F filings for Q4 2023.